Stevanato Group S.p.A.: Stevanato Group Reports First Quarter 2022 Financial Results

- The Company is Maintaining its Fiscal 2022 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical

Related Keywords

United States ,United Kingdom ,Belarus ,China ,Italy ,Indiana ,Zhangjiagang ,Sichuan ,Canada ,Russia ,Ukraine ,Italian ,Franco Moro ,Franco Stevanato ,Exchange Commission On ,Company Investor Relations ,Company Is ,Solutions Segment ,Development Expenses ,European Union ,Stevanato Group ,Stevanato Group Board Of Directors ,Diagnostic Solutions ,Chief Executive Officer ,Diagnostic Solutions Segment ,Engineering Segment ,Stevanato Group Board ,European Time ,Financial Information ,Investor Relations ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Marketing Expenses ,Administrative Expenses ,Constant Currency Revenue ,Adjusted Operating Profit ,Adjusted Operating Profit Margin ,Adjusted Net Profit ,Adjusted Diluted ,Capital Employed ,Net Cash ,Free Cash Flow ,Constant Currency ,Operating Profit ,Income Taxes ,Italian Tax ,Intangible Assets ,Net Profit ,New Plants ,Stevanato ,Group ,Reports ,First ,Quarter ,022 ,Financial ,Results ,